Omeprazole Biogaran Conseil (Omeprazole)

Omeprazole belongs to the proton pump inhibitor class and is indicated for several acid‑related gastrointestinal disorders.

• Gastro‑esophageal reflux disease (GERD): relieves heartburn and esophageal irritation by decreasing gastric acid production.
• Peptic ulcer disease: promotes ulcer healing and prevents recurrence by maintaining a higher gastric pH.
• Zollinger‑Ellison syndrome: controls excessive acid secretion associated with gastrin‑producing tumors.
• NSAID‑induced ulcer prophylaxis: reduces the risk of ulcer formation in patients requiring long‑term non‑steroidal anti‑inflammatory therapy.

• Omeprazole irreversibly binds to the H+/K+‑ATPase enzyme (the gastric proton pump) on the secretory surface of parietal cells, inhibiting the final step of acid secretion. By blocking this pump, it raises gastric pH, thereby decreasing acidity and allowing healing of acid‑related lesions. The inhibition persists until new proton pumps are synthesized, providing prolonged acid suppression after a single dose.

Omeprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Headache: mild to moderate pain often resolving without intervention.
• Abdominal pain: discomfort or cramping in the stomach area.
• Nausea: feeling of queasiness that may lead to vomiting.
• Diarrhea: loose, watery stools.
• Flatulence: excess gas and bloating.
• Constipation: infrequent or difficult bowel movements.

Serious or Rare Side Effects

• Severe allergic reactions (anaphylaxis): rash, swelling, difficulty breathing.
• Clostridioides difficile infection: severe diarrhea due to bacterial overgrowth.
• Hypomagnesemia: low magnesium levels with prolonged use, causing muscle cramps or arrhythmias.
• Bone fractures: increased risk with long‑term therapy.
• Elevated liver enzymes: signs of hepatic stress.
• Stevens‑Johnson syndrome: rare, life‑threatening skin reaction.

Before initiating omeprazole therapy, consider the following precautions.

• Assess renal function: adjust use in patients with severe renal impairment.
• Monitor magnesium levels: prolonged therapy may cause hypomagnesemia.
• Avoid concomitant use with contraindicated drugs: e.g., atazanavir or nelfinavir.
• Use caution in patients with liver disease: dose adjustments may be required.
• Store at room temperature: keep in the original pack, protect from moisture.

Omeprazole can affect the pharmacokinetics of several medicines.

Major Interactions (Avoid)

• Clopidogrel: reduced antiplatelet effect, increasing cardiovascular risk.
• Atazanavir: decreased absorption leading to subtherapeutic antiviral levels.
• High‑dose methotrexate: increased toxicity due to reduced renal clearance.

Moderate Interactions (Monitor Closely)

• Warfarin: possible increase in INR, requiring more frequent monitoring.
• Diazepam: elevated serum concentrations, enhancing sedative effects.
• Digoxin: potential rise in plasma levels, necessitating dose adjustment.